Adeno-associated virus (AAV) vectors are highly efficient for liver-targeted gene delivery in murine models and show promise in early phase human clinical trials. This efficiency is capsid-dependent and was only achieved after discovery that the AAV2 vector genome could be trans-encapsidated into the capsids of other AAV serotypes. This confers novel host-vector biology and target tissue tropism. Optimal exploitation of the growing number of AAV vector pseudo-serotypes, however, requires detailed contextdependent characterisation of transduction performance. In this study, we compared the pattern and efficiency of gene delivery to the adult mouse liver following intraportal and intraperitoneal injection of vectors pseudo-serotyped with known hepatotropic capsids from AAV type 7, 8, 9 and rhesus 10. Vectors pseudo-serotyped with these hepatotropic capsids proved relatively efficient irrespective of administration route, with higher transgene expression in males despite equivalent vector genome delivery in females. Transgene expression was predominantly centrilobular in contrast to the AAV2 capsid, which gave a periportal pattern of expression. Most intriguingly, vector genome performance appeared to be delivery route-dependent, consistent with the possibility of in vivo capsid modification. These data not only inform the experimental use of AAV vectors, but also provide insight into novel aspects of host-vector biology requiring further focused analysis.
INTRODUCTION
Vectors based on adeno-associated virus (AAV) are currently the gene transfer system of choice for liver-targeted gene delivery. The vast majority of pre-clinical studies have been performed in murine models, where optimally configured AAV vectors are capable of achieving highly efficient liver-wide transduction of hepatocytes and relatively stable long-term transgene expression with resultant correction of multiple genetic/metabolic liver disease phenotypes. 1 Impressive results have also been obtained in large animal models including primates [2] [3] [4] and dogs, 5, 6 and encouraging results have recently been reported in a human livertargeted clinical trial for factor IX deficiency. 7 Additional attractive features of the AAV vector system include a favourable safety profile and relatively weak induction of innate immune responses compared with other virus-based vector systems. 8 The impressive efficacy of AAV in the murine liver was only achieved after discovery that the prototypic AAV type 2 genome (AAV2) could be cross-packaged into the capsids of other AAV isolates, 9 a process known as pseudo-serotyping. Vectors bearing the capsid from AAV type 8 (AAV2/8) were the first to be shown to be hepatotropic in the mouse and it was quickly appreciated that pseudo-serotyping not only modifies vector tropism, but also confers other potentially important capsid-specific properties on AAV vectors. These properties include differences in intracellular and transcellular trafficking, and post-entry processing such as rates of uncoating in the nucleus, but have yet to be studied systematically. [10] [11] [12] Another advantage of pseudo-serotyping is that it has the potential to allow vector delivery where prior exposure to wild-type AAV infection or recombinant AAV has resulted in capsid-specific immune responses. [13] [14] [15] In an earlier study of liver-directed gene transfer in the mouse, we found that intraperitoneal (i.p.) delivery of an AAV2/8 vector was highly efficient and equally effective in the neonatal, juvenile and adult mouse, 16 thus obviating the need for direct intraportal or tail vein delivery as previously used in adult mice. 17 The mechanism by which AAV2/8 vectors reach the liver after i.p. delivery remains poorly understood but may involve lymphatic drainage via the thoracic duct and/or direct access to the portal circulation via transcytosis. 11 Whatever the mechanism, it is plausible that other known murine liver tropic pseudo-serotypes may exhibit different relative efficacy for liver-targeted delivery when delivered via the i.p. and intravascular routes. In the current study, we therefore set out to extend our previous work with AAV2/8 by comparing the efficacy and pattern of gene delivery to the liver with three other murine liver tropic capsids following i.p. and intraportal vein (p.v.) delivery.
RESULTS AND DISCUSSION
A previously described AAV2 vector construct 16 encoding enhanced green fluorescent protein (eGFP) under the transcriptional control of a liver-specific promoter was packaged into the capsids of AAV serotypes 2, 7, 8, 9 and rhesus (rh)10, and a dose of 5 Â 10 10 vector genomes per mouse delivered to young adult C57BL/6 mice via either i.p. or p.v. injection. Four weeks after injection livers were harvested for analysis. Histological assessment of eGFP expression patterns using fluorescence microscopy showed robust transduction following both routes of delivery across all four hepatotropic capsids relative to AAV2/2 ( Figure 1 ). Transgene expression was also higher in males than females following transduction with the hepatotropic capsids, and exhibited a predominantly perivenous pattern in both sexes as previously described for AAV2/8 vectors in mice. 16, 18 Interestingly AAV2/2, the least well-performing vector, gave a distinctly periportal pattern of expression that was independent of gender and route of delivery (Figure 1 ). To further explore this observation, laser capture micro-dissection and quantitative PCR were used to establish vector genome distribution across the hepatic lobule. We have previously shown that after AAV2/8 delivery, there are more vector genomes in the perivenous region of the lobule. 18 Here, we show, after AAV2/2 delivery, a predominance of vector genome in the periportal region ( Figure 2 ). Taken together these data show a direct correlation between vector genome distribution and transgene expression for both AAV2/2 ( Figure 2 ) and AAV2/8, confirming that vector genome entry into hepatocytes varies across the hepatic lobule and is a major determinant of the resulting pattern of transgene expression for these pseudo-serotypes. This observation of capsiddependent patterns of expression within a species compliments the recently reported finding of species-dependent patterns of expression across the hepatic lobule for a given capsid. 19 For AAV2/8, the predominantly perivenous pattern of expression observed in mice is also observed in dogs, whereas a predominantly periportal pattern of expression is seen in cynomologus and rhesus macaque liver. Given the phenomenon of metabolic zonation where functions such as ureagenesis are expressed in gradients across the hepatic lobule, 20 these findings add new dimensions to capsid selection when targeting metabolic liver disease. Figure 1 . Patterns of transgene expression across the hepatic lobule in adult mice following AAV-mediated transduction. Livers were harvested 4 weeks after vector delivery and the patterns of eGFP expression examined in liver sections by fluorescence microscopy. Central veins were identified by immuno-histochemical staining of glutamine synthetase. Vector pseudo-serotype, routes of delivery and recipient gender are indicated. Images were captured using the same exposure time (500 ms) and gain (2) for all pseudo-serotypes except AAV2/2 where longer exposure (1 s) and higher gain (16) were used to show the pattern of transduction more clearly. The patterns of transduction shown across the hepatic lobule are representative of n ¼ 3 or 4 animals per treatment group. There was substantial inter-mouse variation in transgene expression within treatment groups with representative levels best evaluated by liver lysate fluorometry. Scale bar ¼ 100 mm. To more fully characterise liver-targeted gene transfer for each vector pseudo-serotype as a function of route of delivery and recipient gender, transgene expression and vector genome copy numbers were quantified by fluorometry and quantitative PCR, respectively ( Figure 3 ). Transgene expression was consistently two to threefold higher in males than females for all hepatotropic capsids examined, irrespective of the route of delivery (Figures 3a  and b) . Vector genome copy numbers, however, were remarkably similar in male and female livers (Figures 3c and d) . Genderdependent differences in transgene expression in the liver at a given AAV vector dose have been previously reported using multiple different capsids, 18, [21] [22] [23] [24] but a detailed understanding of the underlying mechanisms remains elusive. For vectors bearing the type 2 and 5 capsids, higher levels of transduction in male mice has been shown to correlate with increased recovery of AAV vector genomes from the liver. 21 This correlation does not hold for the type 8 capsid, however, where despite higher levels of transgene expression, equivalent levels of vector genome have been found in the male and female liver. 25 Our data not only confirm this later observation, but extend it to three additional hepatotropic vector pseudo-serotypes, AAV2/7, 2/9 and 2/rh10. Collectively, these data suggest that multiple mechanisms are involved and influenced by capsid-dependent intracellular trafficking pathways. [26] [27] [28] [29] [30] At least for AAV2-and 5-based vectors, androgen-dependent post-entry events have been implicated, specifically the possibility that higher binding of host hepatocellular nuclear proteins to the rep-binding site of the vector-inverted terminal repeats observed in male mice might mediate increased vector genome stability/accumulation. 21 Substantial further analysis is required to better resolve the mechanisms involved, including the possibility that vector genomes might be preferentially sequestered in non-expressing non-parenchymal cell types in the female liver, such as Kupffer and endothelial cells.
Route of delivery also affects vector activity. While i.p. and p.v. delivery using hepatotropic pseudo-serotypes both gave relatively robust transgene expression, p.v. delivery was superior for all but the rh10 capsid which performed marginally better via the i.p. route (Figures 3a and b) . Vector genome copy numbers were also similar following i.p. and p.v. delivery (Figures 3c and d) , but showed intriguing route-dependent variation in level of transgene expression per vector genome detected (Figures 3e and f) , most notably for the type 7, 8 and rh10 capsids. The level of transgene expression per vector genome (specific activity) was greater when delivered using the type 8 capsid via the p.v. than i.p. routes, while the converse applied for the type 7 and rh10 capsids. This data suggest that the intracellular processing of vectors bearing these capsids is influenced by the route of delivery, which further implies vector modification en route to the liver with different routes conferring different effects. For example, the rh10 capsid might undergo favourable proteolytic or other modifications in the peritoneum or during transit to the vascular compartment via undefined pathways that may include drainage via the lymphatics into the systemic circulation or transcytosis 11, 31 into the portal To provide a measure of the relative specific activity of vector genomes recovered from the liver, eGFP expression data was divided by the vector genome copy number data for each treatment group (e, f ). Error bars represent mean±s.e.m. for each treatment group (n ¼ 3 or 4). Asterisks indicated statistically significant differences (Pp0.05) between the routes of delivery for specific treatment groups (nonparametric Mann-Whitney U-test).
circulation. Differential protease sensitivity among AAV capsid serotypes has been demonstrated in vitro 32 making similar more subtle effects in vivo plausible, and these in turn could theoretically influence events along the transduction pathway, including intracellular trafficking and vector genome uncoating in the nucleus. 10, 29 In summary, these results show that each of the hepatotropic capsids tested confers robust transgene expression in the adult mouse liver following delivery by either the p.v. or i.p. routes. In contrast to AAV2/2, which gave a previously unreported periportal pattern of expression, all conferred higher levels of transgene expression in the perivenous region of the hepatic lobule and performed better in male recipients. These capsid-dependent patterns correlated with the distribution of vector genomes across the hepatic lobule pointing to differences in vector entry into hepatocytes as the primary mechanism. The gender-dependent differences appeared to be mediated by post-entry events as male and female livers, including parenchymal and non-parenchymal cells, contained similar numbers of vector genomes. Finally, the levels of transgene expression per vector genome, a measure of specific activity, showed both capsid and route-dependence consistent with the possibility of vector modification in vivo en route to the liver. Together these data further emphasise the importance of capsid selection for specific applications, the utility and procedural simplicity of i.p. injection, and the need for ongoing research into the host-vector biology of individual AAV vector pseudo-serotypes.
MATERIALS AND METHODS

Vector production and titration
Vector stocks were produced by triple transfection of HEK293 cells as previously described. 16 Briefly, plasmids included pLSP1-eGFP (eGFP under transcriptional control of a liver specific human a1-antitrypsin promoter plus two copies of the human apolipoprotein enhancer), pXX6 (adenoviral helper functions) and a plasmid containing the appropriate capsid sequence (pXX2, pAAV2/7, p5E18-VD2/8, pAAV2/9sw, pAAV2/rh10). Titre was assigned by real-time quantitative PCR using the Maxima Probe Master Mix (Fermentas, Glen Burnie, MD, USA) with a primer and probe set directed to the WPRE sequence. 33 Animal studies Animal care and experimental procedures were evaluated and approved by the CMRI and CHW Animal Care and Ethics Committee. Male and female C57Bl/6 mice, at 8-10 weeks of age, were injected with 5 Â 10 10 vector genomes via the p.v. (50 ml volume delivered over B1 min) or i.p. (100 ml volume) route as previously described. 16 Mice were culled 4 weeks post injection. Liver tissues for vector genome and fluorometric analyses were snap frozen in liquid nitrogen and stored at À 80 1C. Liver required for immunofluoresecence studies was fixed overnight in 4% (w/v) paraformaldehyde, cryoprotected in 10-30% (w/v) sucrose before freezing in Optimal Cutting Temperature (OCT) compound (Tissue-Tek, Sakura Finetek USA, Torrance, CA, USA).
Analysis of GFP expression
The pattern of eGFP expression across liver sections was examined as previously described. 18 Briefly, 5 mm frozen sections were prepared and counterstained for glutamine synthetase (GS) using an anti-GS rabbit polyclonal (Abcam, Cambridge, UK) and a donkey anti-rabbit Alexa 594 secondary antibody (Invitrogen, Carlsbad, CA, USA). Sections were imaged with an Olympus BX51 fluorescent microscope (Olympus, Centre Valley, PA, USA) and a SPOT enhanced camera using SPOT software version 4.0.1 (Diagnostic Instruments, Sterling Heights, MI, USA).
For analysis of eGFP in whole liver lysates, 0.05-0.1 g of liver was homogenised and sonicated in lysis buffer (0.5% v/v Triton X-100, 1 Â Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany), 0.01 M Hepes) before total protein in lysates was determined (DC Protein assay; BioRad, Hercules, CA, USA). The level of eGFP in each sample was calculated based on a standard curve prepared using recombinant eGFP protein (BioVision Research Products, Mountain View, CA, USA) with analysis on a VICTOR 3 multi-label reader (PerkinElmer, Boston, MA, USA).
Vector genome quantification in whole liver and after laser capture micro-dissection
For detection of vector genomes in whole liver, DNA was extracted using standard phenol/chloroform and ethanol precipitation methods. 34 Samples for laser capture micro-dissection were collected and prepared as previously described. 18 Vector copy number in both whole liver and laser capture micro-dissection samples was determined by quantitative PCR with primer and probe to the WPRE sequence as described above. Sample normalisation was performed using primers to glyceraldehyde 3-phosphate dehydrogense (5 0 -ACGGCAAATTCAACGGCAC-3 0 (sense) and 5 0 -TAGTGGGGTCTCGCTCCTGG-3 0 (antisense)) with QuantiTect Sybr Green PCR kit (Qiagen, Valencia, CA, USA).
